These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32920205)

  • 1. A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703.
    DeFilipp Z; Burns LJ; Jaglowski SM; Leppin AL; Pavletic S; Waldman B; Weisdorf DJ; Wood WA; Khera N
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):e305-e308. PubMed ID: 32920205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
    Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
    Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
    Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
    Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
    Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New era of GVHD prophylaxis using posttransplant cyclophosphamide].
    Sugita J
    Rinsho Ketsueki; 2024; 65(4):272-281. PubMed ID: 38684438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.
    Bejanyan N; Pidala JA; Wang X; Thapa R; Nishihori T; Elmariah H; Lazaryan A; Khimani F; Davila ML; Mishra A; Faramand R; Jain MD; Ochoa L; Perez LE; Liu H; Alsina M; Kharfan-Dabaja MA; Fernandez H; Nieder ML; Locke FL; Anasetti C; Ayala E
    Blood Adv; 2021 Mar; 5(5):1154-1163. PubMed ID: 33635333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
    Shah MV; Saliba RM; Rondon G; Chen J; Soebbing D; Rus I; Alousi A; Oran B; Kebriaei P; Qazilbash M; Parmar S; Hosing C; Khouri IF; Popat UR; Champlin RE; Ciurea SO
    Bone Marrow Transplant; 2019 Apr; 54(4):601-606. PubMed ID: 30337700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes.
    Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ
    J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bykova TA; Chukhlovin AB; Pevtcov DE; Bondarenko SN; Afanasyev BV
    Eur J Haematol; 2018 May; 100(5):395-402. PubMed ID: 29360184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
    Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
    Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.
    Farhadfar N; Burns LJ; Mupfudze T; Shaw BE; Bollard CM; Devine SM; Horowitz MM; Jones RJ; Murthy HS; Wingard JR; Lee SJ
    Transplant Cell Ther; 2021 Feb; 27(2):183.e1-183.e7. PubMed ID: 33045387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.